Abstract
The clinical behavior and molecular pathology of prostate cancer is highly variable. Current "traditional" prognostic markers cannot reliably distinguish the potentially life-threatening cancer from indolent cancer. Identification of additional new predictors of cancer aggressiveness is therefore urgently required. This communication is aimed at a brief review of new biomarkers in prostate cancer diagnostics and prognostics. Pubmed systematic search was performed to collect both original and review articles addressing prostate cancer prognostic biomarkers using key words genetics, prostate cancer, biomarkers and prognosis. The development of molecular and immunohistochemical methods enabled the identification of potential biomarkers in relation to diagnosis and prognosis. Numerous promising markers and approaches have been identified. Some of these markers may be translated into clinical practice after verification in larger prospective trials in future and can help to determine diagnosis and prognosis of CaP more accurately.
Highlights
Prostate Cancer (PCa) is most common nondermatologic malignancy of men in Western Europe (Jemal et al, 2009; Ziaran et al, 2009)
Most CaP are classified into a single group of adenocarcinomas, there is no universal molecular path of CaP development
These alterations, when identified, can be in turn used as biomarkers for prognosis of CaP and other cancers
Summary
Prostate Cancer (PCa) is most common nondermatologic malignancy of men in Western Europe (Jemal et al, 2009; Ziaran et al, 2009). This article provides review of current most promising molecular and immunohistochemical biomarkers in CaP diagnosis, prognosis and clinical behavior.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
